CN103173410A - 用于刺激树突状细胞成熟的组合物以及方法 - Google Patents
用于刺激树突状细胞成熟的组合物以及方法 Download PDFInfo
- Publication number
- CN103173410A CN103173410A CN2013100494026A CN201310049402A CN103173410A CN 103173410 A CN103173410 A CN 103173410A CN 2013100494026 A CN2013100494026 A CN 2013100494026A CN 201310049402 A CN201310049402 A CN 201310049402A CN 103173410 A CN103173410 A CN 103173410A
- Authority
- CN
- China
- Prior art keywords
- dendritic cell
- cell
- ifn
- nutrient solution
- maturation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000004041 dendritic cell maturation Effects 0.000 title abstract 4
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 187
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 50
- JGSARLDLIJGVTE-MBNYWOFBSA-M benzylpenicillin(1-) Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-M 0.000 claims abstract description 49
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 45
- 210000004027 cell Anatomy 0.000 claims abstract description 23
- 230000035800 maturation Effects 0.000 claims description 39
- 230000000638 stimulation Effects 0.000 claims description 27
- 235000015097 nutrients Nutrition 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 7
- 230000005975 antitumor immune response Effects 0.000 claims description 6
- 239000012679 serum free medium Substances 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 26
- 102000013462 Interleukin-12 Human genes 0.000 abstract description 18
- 108010065805 Interleukin-12 Proteins 0.000 abstract description 18
- 230000004071 biological effect Effects 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 7
- 238000004113 cell culture Methods 0.000 abstract description 5
- 238000009169 immunotherapy Methods 0.000 abstract description 5
- 230000003248 secreting effect Effects 0.000 abstract description 4
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 238000004088 simulation Methods 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 230000000118 anti-neoplastic effect Effects 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000012258 culturing Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 229940029030 dendritic cell vaccine Drugs 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000012930 cell culture fluid Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 2
- -1 CD86 Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 2
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 2
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 101001075055 Spinacia oleracea 50S ribosomal protein L19, chloroplastic Proteins 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310049402.6A CN103173410B (zh) | 2013-02-07 | 2013-02-07 | 用于刺激树突状细胞成熟的组合物以及方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310049402.6A CN103173410B (zh) | 2013-02-07 | 2013-02-07 | 用于刺激树突状细胞成熟的组合物以及方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103173410A true CN103173410A (zh) | 2013-06-26 |
CN103173410B CN103173410B (zh) | 2014-12-24 |
Family
ID=48633602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310049402.6A Active CN103173410B (zh) | 2013-02-07 | 2013-02-07 | 用于刺激树突状细胞成熟的组合物以及方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103173410B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103602634A (zh) * | 2013-11-19 | 2014-02-26 | 山东迪博生物技术有限公司 | Dc细胞的制备方法及其在制备抗肿瘤细胞制剂中的应用 |
CN106701680A (zh) * | 2016-11-30 | 2017-05-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进树突状细胞成熟的组合因子及培养树突状细胞的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106544319A (zh) * | 2016-01-24 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法 |
CN107779433A (zh) * | 2016-08-30 | 2018-03-09 | 天津市康婷生物工程有限公司 | 便捷的刺激nk细胞增殖和分化的饲养层制备方法 |
-
2013
- 2013-02-07 CN CN201310049402.6A patent/CN103173410B/zh active Active
Non-Patent Citations (5)
Title |
---|
SAORI NAKAHARA ET AL.: "Dendritic Cells Stimulated with a Bacterial Product, OK-432, Efficiently Induce Cytotoxic T Lymphocytes Specific to Tumor Rejection Peptide", 《CANCER RES》 * |
SNIJDERS A ET AL.: "High-level IL-12 production by human dendritic cells requires two signals.", 《INT IMMUNOL.》 * |
周晔等: "脐血树突细胞无血清培养基体外培养及免疫学特征", 《中国实用妇科与产科杂志》 * |
王静: "OK-432联合聚肌胞诱导小鼠树突状细胞成熟及其抗损伤作用", 《中国优秀硕士学位论文全文数据库》 * |
陈月等: "IFN-γ促进树突状细胞分化成熟的实验研究", 《现代检验医学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103602634A (zh) * | 2013-11-19 | 2014-02-26 | 山东迪博生物技术有限公司 | Dc细胞的制备方法及其在制备抗肿瘤细胞制剂中的应用 |
CN103602634B (zh) * | 2013-11-19 | 2015-09-02 | 山东迪博生物科技股份有限公司 | Dc细胞的制备方法及其在制备抗肿瘤细胞制剂中的应用 |
CN106701680A (zh) * | 2016-11-30 | 2017-05-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种促进树突状细胞成熟的组合因子及培养树突状细胞的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103173410B (zh) | 2014-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Muthuswamy et al. | PGE2 transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells | |
CN103756963B (zh) | 一种体外扩增nk细胞的方法 | |
KR20120093978A (ko) | 항원 특이적 t 세포의 증식 방법 | |
Vopenkova et al. | Complex evaluation of human monocyte‐derived dendritic cells for cancer immunotherapy | |
Van den Bergh et al. | Monocyte-derived dendritic cells with silenced PD-1 ligands and transpresenting interleukin-15 stimulate strong tumor-reactive T-cell expansion | |
CN105087488A (zh) | 一种肿瘤抗原诱导的dc-cik细胞的制备方法及应用 | |
Wei et al. | Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination | |
de Haar et al. | Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation | |
Thordardottir et al. | Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo | |
CN103173410B (zh) | 用于刺激树突状细胞成熟的组合物以及方法 | |
JP5856025B2 (ja) | 単球またはnk細胞を入手する方法 | |
CN104491853A (zh) | 一种人树突状细胞肿瘤疫苗的制备方法 | |
CN104711224A (zh) | 一种提高人Vδ2T细胞扩增效率的体外培养方法及应用 | |
CN104073467A (zh) | 一种人dccik免疫活性细胞的制备方法 | |
Yang et al. | Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia | |
Delirezh et al. | Generation of mature monocyte-derived dendritic cells in the presence of heparin and monocyte conditioned medium: phenotypic and functional comparison | |
CN106701680A (zh) | 一种促进树突状细胞成熟的组合因子及培养树突状细胞的方法 | |
Rouas et al. | Dendritic cells generated in clinical grade bags strongly differ in immune functionality when compared with classical DCs generated in plates | |
Woo et al. | Role of natural killer cell function in dendritic cell-based vaccines | |
CN103266086A (zh) | 一种有效递呈胃癌抗原的树突状细胞的制备方法 | |
CN103602634B (zh) | Dc细胞的制备方法及其在制备抗肿瘤细胞制剂中的应用 | |
CN105219727A (zh) | 一种用于激活结直肠癌特异性免疫反应的试剂盒 | |
Nguyen et al. | Differentiation of monocyte-derived dendritic cells under the influence of platelets | |
CN105219723A (zh) | 一种用于激活胃癌特异性免疫反应的试剂盒 | |
CN105219717A (zh) | 一种一型极化树突状细胞及其诱导方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU YIYANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: XIA JIANCHUAN Effective date: 20150806 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150806 Address after: 510000, Guangzhou International Biological Island, spiral four, No. 7, standard industrial units, phase third, two, 7, 701, 702, units Patentee after: Guangzhou benefit Biotechnology Co., Ltd. Address before: 615, room 651, 510000 Dongfeng Dong Road, Guangdong, Guangzhou Patentee before: Xia Jianchuan |